Crinetics Pharmaceuticals (CRNX) Depreciation & Amortization (CF) (2017 - 2026)

Crinetics Pharmaceuticals' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 25.41% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $4.1 million (up 27.47% YoY), while the FY2025 annual figure was $3.9 million, up 39.68% from the prior year.
• Depreciation & Amortization (CF) was $1.2 million for Q1 2026 at Crinetics Pharmaceuticals, up from $994000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.2 million in Q1 2026 to a low of $215000.0 in Q2 2022.
• Historically, Depreciation & Amortization (CF) has averaged $583294.1 across 5 years, with a median of $474000.0 in 2024.
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) retreated 6.52% in 2022, then soared 200.76% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $280000.0 in 2022, then slipped by 6.43% to $262000.0 in 2023, then jumped by 200.76% to $788000.0 in 2024, then advanced by 26.14% to $994000.0 in 2025, then grew by 16.7% to $1.2 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.2 million (Q1 2026), $994000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.